Antisense Therapeutics Limited Stock Performance
| ATHJF Stock | USD 0 0.00 0.00% |
The firm shows a Beta (market volatility) of -1.87, which signifies a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Antisense Therapeutics are expected to decrease by larger amounts. On the other hand, during market turmoil, Antisense Therapeutics is expected to outperform it. At this point, Antisense Therapeutics has a negative expected return of -3.73%. Please make sure to confirm Antisense Therapeutics' jensen alpha, skewness, as well as the relationship between the Skewness and day median price , to decide if Antisense Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Antisense Therapeutics Limited has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's forward-looking indicators remain nearly stable which may send shares a bit higher in February 2025. The current disturbance may also be a sign of long-run up-swing for the company stockholders. ...more
| Begin Period Cash Flow | 6 M | |
| Total Cashflows From Investing Activities | -3913.00 | |
| Free Cash Flow | -7.8 M |
Antisense |
Antisense Therapeutics Relative Risk vs. Return Landscape
If you would invest 5.66 in Antisense Therapeutics Limited on October 23, 2024 and sell it today you would lose (5.48) from holding Antisense Therapeutics Limited or give up 96.82% of portfolio value over 90 days. Antisense Therapeutics Limited is currently producing negative expected returns and takes up 16.7397% volatility of returns over 90 trading days. Put another way, most equities are less risky on the basis of their return distribution than Antisense, and majority of traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Antisense Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Antisense Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Antisense Therapeutics Limited, and traders can use it to determine the average amount a Antisense Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.2226
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ATHJF |
Estimated Market Risk
| 16.74 actual daily | 96 96% of assets are less volatile |
Expected Return
| -3.73 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.22 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Antisense Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Antisense Therapeutics by adding Antisense Therapeutics to a well-diversified portfolio.
Antisense Therapeutics Fundamentals Growth
Antisense Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Antisense Therapeutics, and Antisense Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Antisense Pink Sheet performance.
| Return On Equity | -0.43 | |||
| Return On Asset | -0.25 | |||
| Operating Margin | (3.28) % | |||
| Current Valuation | 27.82 M | |||
| Shares Outstanding | 669.04 M | |||
| Price To Earning | (3.62) X | |||
| Price To Book | 3.05 X | |||
| Price To Sales | 24.46 X | |||
| Revenue | 1.78 M | |||
| EBITDA | (7.52 M) | |||
| Cash And Equivalents | 19.23 M | |||
| Cash Per Share | 0.03 X | |||
| Total Debt | 227.4 K | |||
| Debt To Equity | 0.01 % | |||
| Book Value Per Share | 0.03 X | |||
| Cash Flow From Operations | (7.81 M) | |||
| Earnings Per Share | (0.01) X | |||
| Total Asset | 22.44 M | |||
| Retained Earnings | (53 M) | |||
| Current Asset | 5 M | |||
| Current Liabilities | 1000 K | |||
About Antisense Therapeutics Performance
By analyzing Antisense Therapeutics' fundamental ratios, stakeholders can gain valuable insights into Antisense Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Antisense Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Antisense Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Antisense Therapeutics Limited engages in the research and development of novel antisense pharmaceuticals in Australia. Antisense Therapeutics Limited was incorporated in 2000 and is based in Toorak, Australia. Antisense Therapeutics operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange.Things to note about Antisense Therapeutics performance evaluation
Checking the ongoing alerts about Antisense Therapeutics for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Antisense Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Antisense Therapeutics is not yet fully synchronised with the market data | |
| Antisense Therapeutics generated a negative expected return over the last 90 days | |
| Antisense Therapeutics has high historical volatility and very poor performance | |
| Antisense Therapeutics has some characteristics of a very speculative penny stock | |
| The company reported the revenue of 1.78 M. Net Loss for the year was (5.81 M) with profit before overhead, payroll, taxes, and interest of 1.71 M. | |
| Antisense Therapeutics Limited has accumulated about 19.23 M in cash with (7.81 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.03, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 19.0% of the company shares are held by company insiders |
- Analyzing Antisense Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Antisense Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Antisense Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Antisense Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Antisense Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Antisense Therapeutics' pink sheet. These opinions can provide insight into Antisense Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Antisense Pink Sheet analysis
When running Antisense Therapeutics' price analysis, check to measure Antisense Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Antisense Therapeutics is operating at the current time. Most of Antisense Therapeutics' value examination focuses on studying past and present price action to predict the probability of Antisense Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Antisense Therapeutics' price. Additionally, you may evaluate how the addition of Antisense Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments |